---
title: "Zai Lab Limited (ZLAB.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ZLAB.US.md"
symbol: "ZLAB.US"
name: "Zai Lab Limited"
industry: "Biotechnology"
datetime: "2026-05-19T12:57:21.239Z"
locales:
  - [en](https://longbridge.com/en/quote/ZLAB.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ZLAB.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ZLAB.US.md)
---

# Zai Lab Limited (ZLAB.US)

## Company Overview

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH. The company was incorporated in 2013 and is based in Pudong, China.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.zailaboratory.com](https://www.zailaboratory.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:13.000Z

**Overall: C (0.52)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 91 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 8.36% |  |
| Net Profit YoY | 29.34% |  |
| P/B Ratio | 3.15 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 2086684337.54 |  |
| Revenue | 453280000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -24.19% | E |
| Profit Margin | -39.29% | E |
| Gross Margin | 61.52% | A |
| Revenue YoY | 8.36% | B |
| Net Profit YoY | 29.34% | B |
| Total Assets YoY | -6.61% | D |
| Net Assets YoY | -18.35% | E |
| Cash Flow Margin | 56.71% | C |
| OCF YoY | 8.36% | B |
| Turnover | 0.40 | C |
| Gearing Ratio | 39.59% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Zai Lab Limited",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "8.36%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "29.34%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "3.15",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "2086684337.54",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "453280000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-24.19%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-39.29%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "61.52%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "8.36%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "29.34%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-6.61%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-18.35%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "56.71%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "8.36%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.40",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "39.59%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -11.72 | 467/386 | - | - | - |
| PB | 3.15 | 258/386 | 4.76 | 3.44 | 2.79 |
| PS (TTM) | 4.60 | 100/386 | 8.92 | 5.52 | 4.63 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-18T04:00:00.000Z

Total Analysts: **12**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 9 | 75% |
| Overweight | 2 | 17% |
| Hold | 1 | 8% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 18.86 |
| Highest Target | 53.00 |
| Lowest Target | 24.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ZLAB.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ZLAB.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ZLAB.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ZLAB.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**